Enliven Therapeutics Inc. (ELVN)vsVertex Pharmaceuticals Inc (VRTX)
ELVN
Enliven Therapeutics Inc.
$52.97
-1.47%
HEALTHCARE · Cap: $3.80B
VRTX
Vertex Pharmaceuticals Inc
$481.70
-0.34%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
ELVN
Avoid25
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ELVN.
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$481.70
$459.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ELVN
The strongest argument for ELVN centers on Debt/Equity, Altman Z-Score.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ELVN
The primary concerns for ELVN are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ELVN profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.29 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 25/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enliven Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its proprietary therapeutic platforms. With a robust pipeline of advanced drug candidates developed using cutting-edge biopharmaceutical technologies, the company is dedicated to enhancing patient care and quality of life. Enliven's commitment to scientific excellence and its mission to fulfill unmet needs in oncology strategically position it for substantial shareholder value while making a meaningful contribution to the healthcare ecosystem.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?